Precision Logistics for Life Sciences: Biopharmaceutical Third Party Transportation Services Market Set to Grow from USD 8.67 Billion to USD 15.12 Billion by 2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biopharmaceutical Third Party Transportation Services – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Biopharmaceutical Third Party Transportation Services market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6067272/biopharmaceutical-third-party-transportation-services
Market Analysis: Accelerating Growth in Specialized Pharma Logistics
According to the latest market analysis, the global Biopharmaceutical Third Party Transportation Services market was valued at approximately USD 8.67 billion in 2025 and is projected to reach USD 15.12 billion by 2032, growing at a robust CAGR of 8.4% from 2026 to 2032. This strong market growth reflects the rapid expansion of the biopharmaceutical industry, the increasing complexity and temperature sensitivity of biologics (monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, mRNA vaccines), the outsourcing of logistics to specialized third-party providers (3PLs), and the advancement of cold chain technologies, temperature monitoring systems, and intelligent logistics platforms.
For biopharmaceutical supply chain directors, logistics procurement executives, pharmaceutical cold chain investors, and healthcare logistics strategists, this market research signals a high-growth segment where cold chain integrity, real-time monitoring, regulatory compliance, and value-added services (packaging, labeling, temperature monitoring) are critical differentiators in an increasingly competitive market.
Product Definition: Specialized Logistics for Temperature-Sensitive Biologics
Biopharmaceutical third party transportation services refer to transportation services provided by professional logistics companies for biopharmaceutical enterprises, covering the entire logistics solution from production (manufacturing facilities) to distribution (hospitals, pharmacies, clinics, patient homes). This type of service typically includes cold chain transportation (temperature-controlled transport for refrigerated (2-8°C), frozen (-20°C), ultra-low temperature (-70°C to -80°C), and cryogenic (liquid nitrogen vapor phase, below -150°C) products), warehouse management (temperature-controlled storage facilities, typically GxP-compliant (Good Distribution Practice)), and value-added services (packaging (thermal shippers, phase change materials (PCMs), dry ice), labeling (clinical trial labeling, serialization), temperature monitoring (real-time data loggers with GPS and cellular transmission), and other compliance services). These services aim to ensure the safety, stability, and compliance of biopharmaceutical products (such as vaccines (mRNA, viral vector, protein subunit, inactivated), biologics (monoclonal antibodies (mAbs), fusion proteins, cytokines, hormones), gene therapy drugs (AAV (adeno-associated virus) vectors, lentiviral vectors), cell therapy products (CAR-T cells, stem cells), and other advanced therapy medicinal products (ATMPs) during transportation, including protection from temperature excursions, physical damage, light exposure, and delays.
Key Industry Drivers and Market Dynamics
Industry Trend 1: Biopharmaceutical Industry Growth
The most significant driver of biopharmaceutical third-party transportation demand is the global expansion of the biopharmaceutical industry. According to IQVIA’s 2025 Global Biopharmaceutical Market Report, the global biologics market reached USD 450 billion in 2024, growing at 8-10 percent annually, and is projected to reach USD 600-700 billion by 2030. The biologics share of total pharmaceutical market has increased to 35-40 percent. The number of biologic approvals (NDA/BLA) has increased, particularly for immuno-oncology, rare diseases, autoimmune diseases, and gene therapies. As biopharmaceutical production volumes increase (both from large-scale commercial manufacturing and clinical trial supplies), the volume of temperature-sensitive shipments requiring specialized cold chain logistics increases proportionally. Biologics are sensitive to temperature, light, and agitation; maintaining cold chain integrity is essential to prevent aggregation, degradation, and loss of potency.
Industry Trend 2: Cell and Gene Therapy – Ultra-Cold Chain Requirements
A significant industry trend is the emergence of cell and gene therapy (CGT) products, which require extreme cold chain conditions and specialized logistics. According to the Alliance for Regenerative Medicine (ARM) 2025 Annual Report, over 1,200 cell and gene therapy clinical trials are ongoing, with 20+ products approved globally (including CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma), gene therapies (Zolgensma, Luxturna, Hemgenix, Roctavian, Vyjuvek, Elevidys, Lyfgenia, Casgevy). CGT logistics requirements include cryogenic storage (liquid nitrogen dry vapor shippers maintain -150°C or below for cell viability). Chain of identity (COI) and chain of custody (COC) are critical for autologous cell therapies (patient-specific). Logistics must be time-sensitive (autologous cell therapies require coordinated logistics from patient apheresis → manufacturing → return to patient hospital; any delay may compromise product viability). Gene therapy vectors (AAV, lentivirus) require -70°C or -20°C storage depending on formulation. CGT products are high-value (USD 500,000-3,000,000+ per treatment), so logistics failure is catastrophic. Specialized CROs/CDMOs (3PLs) with CGT logistics expertise have emerged. The CGT logistics market is growing at 15-20 percent CAGR, driving growth in the broader biopharmaceutical transportation market.
Industry Trend 3: Mode of Transport Segmentation – Air Transport Leads
The market segments by mode of transport into Air Transport (approximately 45-50 percent of market share, largest segment – preferred for long-distance, time-sensitive shipments (international, cross-continental). Air freight is faster than sea (2-5 days vs. 4-8 weeks). Temperature-controlled air cargo containers (e.g., Envirotainer, Va-Q-tec, CSafe) are used for pharma shipments. Air transport is more expensive than sea but essential for high-value, time-critical biologics and clinical trial supplies. Land Transportation (approximately 25-30 percent – temperature-controlled trucks, vans, and couriers for regional and local distribution; used for last-mile delivery to hospitals, pharmacies, clinics, patient homes; refrigerated (2-8°C) and frozen (-20°C) are common; real-time temperature monitoring and GPS tracking are standard. Sea Transportation (approximately 15-20 percent – lower-cost option for less time-sensitive bulk biologics; used for API (active pharmaceutical ingredient) shipments, bulk drug substance, and some finished products. Temperature-controlled containers (reefer containers) with data loggers are used. Sea freight is slower (4-8 weeks) and has higher risk of temperature excursions, but is cost-effective for high-volume, stable-temperature products. Others (5-10 percent – intermodal combinations). Air transport is the largest segment because many biologics are time-sensitive and high-value, and clinical trial supplies require rapid global distribution. Land transport is essential for last-mile delivery.
Industry Trend 4: Application Segmentation – Vaccine Transportation Largest
By application, the market segments into Vaccine Transportation (approximately 30-35 percent of market share, largest segment – routine immunization vaccines (influenza, HPV, hepatitis B, pneumococcal, rotavirus, MMR, polio, COVID-19). COVID-19 vaccines demonstrated the need for massive, global cold chain logistics capacity. mRNA vaccines require -70°C or -20°C storage, pushing cold chain technology. Vaccine distribution is often managed by public health authorities, UNICEF, WHO, Gavi, and NGOs, as well as commercial vaccine manufacturers (Pfizer, Moderna, GSK, Sanofi, Merck). Drug Distribution and Retail (approximately 25-30 percent – distribution from manufacturers to wholesalers, hospitals, pharmacies, and clinics. Includes both biologics and small molecule drugs; cold chain required for biologics. Blood Products Transportation (approximately 15-20 percent – blood components (red blood cells, platelets, plasma) and plasma-derived products (albumin, IVIG, clotting factors). Blood products have strict temperature and handling requirements. Cell and Gene Therapy Products Transportation (approximately 10-15 percent, fastest-growing at 18-20 percent CAGR – CAR-T therapies, gene therapies, and other ATMPs. Requires cryogenic conditions and chain-of-identity monitoring. Clinical Trial Drug Transportation (approximately 10-15 percent – distribution of investigational drugs to clinical sites globally. Often requires temperature-controlled packaging (validated shippers) and real-time monitoring. Clinical trial logistics are complex due to smaller batch sizes, varied destination countries, customs clearance requirements, and temperature excursions may invalidate trial data. Vaccine transportation is the largest segment due to the volume of vaccines produced and distributed globally (billions of doses annually). Cell and gene therapy is the fastest-growing segment due to the rapid expansion of approved products and clinical trials.
Exclusive Analyst Insight: Regional Landscape – North America Dominates, China Fastest Growing
From my industry analysis perspective, the biopharmaceutical third-party transportation market exhibits distinct regional patterns. North America (US, Canada) holds the largest share (estimated 40-45 percent of market share), due to a mature biopharmaceutical industry, large number of biotech companies, established logistics infrastructure, and regulatory leadership. Major 3PLs (DHL, UPS, FedEx, Kuehne+Nagel, DB Schenker, AmerisourceBergen, McKesson, Cardinal Health, C.H. Robinson, XPO Logistics) have strong presence in North America. Europe holds 25-30 percent market share, with a strong biopharmaceutical industry in Switzerland (Roche, Novartis), Germany (Bayer, BioNTech), France (Sanofi), UK (GSK, AstraZeneca), and other countries. EU GDP (Good Distribution Practice) guidelines require strict temperature control. Asia-Pacific is the fastest-growing region (projected 10-12 percent CAGR), driven by China (China’s biopharmaceutical market is growing at 15-20 percent annually; domestic logistics providers (Sinopharm Group, Huaxin Supply Chain, SF Express, Kerry Logistics (Hong Kong), Shanghai Pharma) are expanding cold chain capabilities; China’s vaccine distribution network is extensive (national immunization program). Sinopharm Group is the largest pharmaceutical distributor in China, offering cold chain logistics. SF Express (courier) has a dedicated pharmaceutical cold chain division. Kerry Logistics (Hong Kong) provides logistics throughout Asia. Shanghai Pharma is a major Chinese pharmaceutical distributor. Market drivers include increasing biopharmaceutical manufacturing in China (domestic innovation and contract manufacturing), government support for cold chain infrastructure, and increasing demand for temperature-controlled logistics for domestic distribution and international exports.
In conclusion, the biopharmaceutical third party transportation services market offers strong, cold-chain-driven growth with a projected USD 15.12 billion market size by 2032. Success factors for logistics providers include global reach (network of hubs and depots), temperature range capability (2-8°C, -20°C, -80°C, cryogenic), real-time monitoring (IoT sensors, GPS tracking), regulatory compliance (GDP, GMP), and value-added services (packaging, labeling, customs clearance, chain-of-identity).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
